Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868724 | 0.81 | ADAM17 (0.52) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL14868680 | 0.78 | NPC1 (0.50) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL28170304 | 0.77 | RAB9A (0.49) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL14868800 | 0.76 | NPC1 (0.51) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL14868679 | 0.75 | ADAM17 (0.49) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL7997473 | 0.75 | NPC1 (0.50) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL10310223 | 0.74 | NPC1 (0.57) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL29074376 | 0.73 | NPC1 (0.55) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL680547 | 0.71 | — | — | |
| SCHEMBL14559633 | 0.71 | ADAM17 (0.57) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ADAM17 4004/4885NPC1 405/4885RAB9A 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.